Neratinib (Fukang (Shanghai) Health Technology)

奈拉替尼 (甫康（上海）健康科技有限责任公司)

Report date: 2025/06/24 09:42:17

Base Information

Drug NameNeratinib (Fukang (Shanghai) Health Technology)
Drug Alias NameCVL009CVL-009
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnti-HER2Epidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-4
Therapy Area/IndicationsSolid tumoursUterine NeoplasmsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesConvalife (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesConvalife (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine NeoplasmsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A